In this week’s EuroBiotech Report, British biotechs already buoyed by the arrival of funds backed by AstraZeneca and Eli Lilly got more reasons to be cheerful when Imperial Innovations outlined plans to raise £150 million ($251 million). And if Neil Woodford gets his way, another early stage-focused fund will be setting up in England. And more.

…read more

Source: Imperial to raise £150M, Prosensa finds caveats for PhIII fail, Orion targets niche next to J&J


0 No comments